Article Names Medical Marijuana, Inc. and AXIM(R) Biotech as Two of “10 Largest Marijuana Companies Raking in Huge Profits”Posted on January 6, 2017
Article Names Medical Marijuana, Inc. and AXIM(R) Biotech as Two of “10 Largest Marijuana Companies Raking in Huge Profits”
SAN DIEGO, CA–(Marketwired – January 06, 2017) – Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded cannabis company in the United States, today announced that the Company was featured in a recent High Times article, “10 Largest Marijuana Companies Raking in Huge Profits.”
Using data from well-respected firm Viridian Capital Advisors, a group of Wall Street analysts and bankers focused on cannabis investing who also maintain a cannabis stock index, the article listed the 10 largest U.S.-listed companies by market cap — nine of which were biotech/Pharmaceutical companies.
Medical Marijuana, Inc. came in at No. 6 on the list of powerhouse companies, and investment AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) came in at No. 5 among the top U.S. cannabis companies. The other top four companies were: 1. GW Pharmaceuticals, 2. Canopy Growth, 3. Insys Therapeutics, 4. Aurora Cannabis.
“With historic, first-ever import approvals for medical cannabis products in Mexico, Columbia and Paraguay, and continued growth of our Brazil business, 2016 was a very exciting year for the Company,” said Medical Marijuana, Inc. CEO, Dr. Stuart Titus. “We applaud the news media for covering developments on the financial side, and for savvy investors who are starting to look into the fastest-growing sector in the US.”
Meanwhile, AXIM has been added to the North American Marijuana Index, which tracks the leading public cannabis companies operating in the United States and Canada.
Owned by MJIC Inc., the North American Marijuana Index includes companies that have achieved a weighted average minimum market capitalization of $30 million USD, daily trading volume of $400,000 USD and share price of $0.10 USD. Companies with more than $5 million USD of revenue over the prior year are exempt from the above trading requirements and the Index currently has 28 constituents.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.